# An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

> **NCT02226458** · PHASE2 · WITHDRAWN · sponsor: **Edison Pharmaceuticals Inc**

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** EPI-743

## Key facts

- **NCT ID:** NCT02226458
- **Lead sponsor:** Edison Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10-31
- **Primary completion:** 2015-11-30
- **Final completion:** 2016-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was halted prior to enrolling.
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226458, "An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02226458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*